All In Biotech

Drug Trial Radar · NCT00792103

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Jan 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
NuPathe Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: * Subject self-examination skin irritation scores * Adverse events * Changes in vital signs and ECG parameters The secondary objective is to evaluate the long term efficacy of NP101 as assessed by: * Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101 This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch). Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.

Conditions

  • Migraine Disorders

Interventions

  • NP101Drug

    NP101 study patch 4 hour application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject Self-examination of Skin IrritationTime frame: 24 hours post patch activation

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Newport Beach, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Fairfield, Connecticut

  • Site not named

    Ocala, Florida

  • Site not named

    Palm Beach Gardens, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Springfield, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Mount Vernon, New York

  • Site not named

    Plainview, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    West Chester, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Wynnewood, Pennsylvania

  • Site not named

    Memphis, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Alexandria, Virginia

  • Site not named

    Virginia Beach, Virginia

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.